Literature DB >> 18178257

Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome.

Bart C Jacobs1, Michiaki Koga, Wouter van Rijs, Karin Geleijns, Pieter A van Doorn, Hugh J Willison, Nobuhiro Yuki.   

Abstract

In 176 patients with Guillain-Barré syndrome the subclass and cross-reactivity of serum IgG antibodies to motor gangliosides was related to preceding infections and clinical phenotypes. Two subgroups of patients were identified. Presence of only IgG1 antibodies was related to diarrhea, positive Campylobacter serology, cross-reactive antibodies to C. jejuni lipo-oligosaccharides and poor outcome. In contrast, having both IgG1 and IgG3 antibodies was related to upper respiratory tract infections, cross-reactive antibodies to Haemophilus influenzae lipo-oligosaccharides and better outcome. These findings support a model in which C. jejuni and H. influenzae infections induce two distinct patterns of cross-reactive antibodies with different clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178257     DOI: 10.1016/j.jneuroim.2007.11.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

1.  Guillain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: a case report.

Authors:  Fotinie Ntziora; Athina Euthimiou; Maria Tektonidou; Anastasios Andreopoulos; Kostas Konstantopoulos
Journal:  J Med Case Rep       Date:  2011-12-04

2.  Peripheral neuropathies: clinical prognostic scales in Guillain-Barré syndrome.

Authors:  Nortina Shahrizaila; Nobuhiro Yuki
Journal:  Nat Rev Neurol       Date:  2011-06-21       Impact factor: 42.937

Review 3.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

Review 4.  How a sugary bug gets through the day: recent developments in understanding fundamental processes impacting Campylobacter jejuni pathogenesis.

Authors:  Christine M Szymanski; Erin C Gaynor
Journal:  Gut Microbes       Date:  2012-03-01

5.  Detection and genotyping of Campylobacter jejuni and Campylobacter coli by use of DNA oligonucleotide arrays.

Authors:  Francesca Marotta; Katiuscia Zilli; Alfreda Tonelli; Lorena Sacchini; Alessandra Alessiani; Giacomo Migliorati; Elisabetta Di Giannatale
Journal:  Mol Biotechnol       Date:  2013-02       Impact factor: 2.695

6.  The virulence factor PEB4 (Cj0596) and the periplasmic protein Cj1289 are two structurally related SurA-like chaperones in the human pathogen Campylobacter jejuni.

Authors:  Avinash Kale; Chatchawal Phansopa; Chatrudee Suwannachart; C Jeremy Craven; John B Rafferty; David J Kelly
Journal:  J Biol Chem       Date:  2011-04-26       Impact factor: 5.157

7.  Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-Barré syndrome mouse model.

Authors:  Rhona McGonigal; Clare I Campbell; Jennifer A Barrie; Denggao Yao; Madeleine E Cunningham; Colin L Crawford; Simon Rinaldi; Edward G Rowan; Hugh J Willison
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

8.  Th1/Th17-mediated Immunity and Protection from Peripheral Neuropathy in Wildtype and IL10-/- BALB/c Mice Infected with a Guillain-Barré Syndrome-associated Campylobacter jejuni Strain.

Authors:  Jean M Brudvig; Matthew M Cluett; Elizabeth U Gensterblum-Miller; James Chen; Julia A Bell; Linda S Mansfield
Journal:  Comp Med       Date:  2022-03-10       Impact factor: 1.565

Review 9.  Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.

Authors:  Nobuhiro Yuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

Review 10.  Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.

Authors:  Ying Wang; Shuang Sun; Jie Zhu; Li Cui; Hong-Liang Zhang
Journal:  Mediators Inflamm       Date:  2015-09-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.